

8 November 2016

Company Announcements Office
Australian Securities Exchange

Vectus Wins Medtech and Pharma category of Australian Technologies Competition

On 2 November 2016, Vectus Biosystems Limited (ASX: VBS) (Vectus or the Company) was announced as the winner of the Medtech and Pharma category of the Australian Technologies Competition. Now in its sixth year, there were 150 entrants across 10 industry sectors in the Competition. This was the first year that the Medtech and Pharma category of the competition was included, with 39 participants from the sector entering the category. Companies were judged on eight criteria, including market potential, business model, technology validation and protection, and their leadership team. Ultimately, the winner was the company that was deemed to have the greatest potential to have a global impact.

“Fibrotic disease contributes to more than 40% of all deaths worldwide, and the market for treating diseases in the heart, lungs, kidneys and liver is estimated to be worth US\$70 billion per year. Currently, there are very few anti-fibrotic drugs available, and those that do exist only slow the progression of disease. Vectus aims to address a massive unmet clinical need,” said Vectus’ Commercial Manager, Dr Duncan Macinnis.

Vectus was founded based on the discoveries of CEO, Dr Karen Duggan. “Vectus has developed a library of more than 1,000 orally-active small molecules drugs. Most importantly, unlike all other companies working in this space, we have demonstrated the ability to reverse fibrosis,” she said.

Ms Sue MacLeman, Managing Director and CEO of MTPConnect, who announced the winner, said, “Congratulations to Karen and the whole team at Vectus Biosystems on winning the Medtech and Pharma category of the Competition. Vectus is developing an exciting compound with anti-fibrotic activity, and if its product development continues to be successful this would address a significant unmet medical need.” MTPConnect is one of six Federal Government Industry Growth Centres, with a focus on the medical technology, biotechnology and pharmaceutical sector, and was responsible for selecting the three category finalists.

Vectus Biosystems Limited

Karen Duggan

Chief Executive Officer and Executive Director